Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy DermTech stock
Learn how to easily invest in DermTech stock.
DermTech Inc is a diagnostics & research business based in the US. DermTech shares (DMTK) are listed on the NASDAQ and all prices are listed in US Dollars. DermTech employs 114 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in DermTech
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – DMTK – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
DermTech stock price (NASDAQ: DMTK)Use our graph to track the performance of DMTK stocks over time.
DermTech shares at a glance
|Latest market close||$12.37|
|52-week range||$11.01 - $84.49|
|50-day moving average||$17.90|
|200-day moving average||$31.62|
|Wall St. target price||$49.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.34|
Buy DermTech shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy DermTech stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
DermTech price performance over time
|1 week (2022-01-18)||-6.22%|
|1 month (2021-12-23)||-31.12%|
|3 months (2021-10-25)||-59.39%|
|6 months (2021-07-23)||-65.16%|
|1 year (2021-01-25)||-72.80%|
|2 years (2020-01-24)||-6.64%|
|3 years (2019-01-25)||20.33%|
|5 years (2017-01-21)||N/A|
|Revenue TTM||$10.8 million|
|Gross profit TTM||$-96,000|
|Return on assets TTM||-22.75%|
|Return on equity TTM||-40.61%|
|Market capitalisation||$367.6 million|
TTM: trailing 12 months
DermTech share dividends
We're not expecting DermTech to pay a dividend over the next 12 months.
Have DermTech's shares ever split?
DermTech's shares were split on a 1:2 basis on 29 August 2019. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your DermTech shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for DermTech shares which in turn could have impacted DermTech's share price.
DermTech share price volatility
Over the last 12 months, DermTech's shares have ranged in value from as little as $11.01 up to $84.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DermTech's is 0.711. This would suggest that DermTech's shares are less volatile than average (for this exchange).
DermTech, Inc. , a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc.
DermTech in the news
What to watch today: Wall Street to open lower after Nasdaq's worst week since March 2020
Stocks making the biggest moves in the premarket: Kohl's, Snap, Peloton and more
Should You Sell DermTech and GoodRx Stocks Right Now?
Frequently asked questionsWhat percentage of DermTech is owned by insiders or institutions?
Currently 9.214% of DermTech shares are held by insiders and 73.347% by institutions. How many people work for DermTech?
Latest data suggests 114 work at DermTech. When does the fiscal year end for DermTech?
DermTech's fiscal year ends in December. Where is DermTech based?
DermTech's address is: 11099 North Torrey Pines Road, La Jolla, CA, United States, 92037 What is DermTech's ISIN number?
DermTech's international securities identification number is: US24984K1051 What is DermTech's CUSIP number?
DermTech's Committee on Uniform Securities Identification Procedures number is: 24984K105
More guides on Finder
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Ask an Expert